11836153001
Roche
cOmplete™, Mini Protease Inhibitor Cocktail
Tablets provided in a glass vial
Synonym(s):
Protease inhibitor
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352204
Recommended Products
form
tablet
usage
sufficient for 25 10mL extraction solution preparations
packaging
vial of 25 tablets
manufacturer/tradename
Roche
technique(s)
tissue processing: suitable
solubility
water: soluble
storage temp.
2-8°C
General description
cOmplete, Mini Protease Inhibitor Tablets, inhibit a broad spectrum of serine, cysteine, and metalloproteases, as well as calpains.
Due to the optimized composition of the tablets, they show excellent inhibition effects, and are well suited for the protection of proteins isolated from animal tissues, plants, yeast, and bacteria.
cOmplete, Mini Protease Inhibitor Tablets contain EDTA and both irreversible and reversible protease inhibitors.
Due to the optimized composition of the tablets, they show excellent inhibition effects, and are well suited for the protection of proteins isolated from animal tissues, plants, yeast, and bacteria.
cOmplete, Mini Protease Inhibitor Tablets contain EDTA and both irreversible and reversible protease inhibitors.
Specificity
For the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
Application
cOmplete™, Mini Protease Inhibitor Cocktail has been used as a
component of
component of
- lysis buffer for lysing glioma tumor samples
- radioimmunoprecipitation (RIPA) protein extraction buffer for homogenization of heart tissues
- resuspension buffer for retinal ganglion cells homogenization
cOmplete™, Mini, is used for the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
cOmplete, Mini, contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete, Mini, to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete, Mini contains EDTA (1 tablet yields a 1 mM EDTA solution in 10 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography.
Alternatively, the product cOmplete, Mini EDTA-free, can be used. These tablets are identical to cOmplete, Mini, with the exception that no EDTA or other chelating agent is present.
cOmplete, Mini Tablets, inhibit proteolytic activity in small extraction volumes (up to 10 ml). If you are working with a larger volume (up to 50 ml) we recommend to use a different cOmplete product. The composition of the cOmplete Tablet is identical to the cOmplete, Mini Tablet, therefore comparable results are achieved with both product types.
cOmplete, Mini, contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete, Mini, to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete, Mini contains EDTA (1 tablet yields a 1 mM EDTA solution in 10 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography.
Alternatively, the product cOmplete, Mini EDTA-free, can be used. These tablets are identical to cOmplete, Mini, with the exception that no EDTA or other chelating agent is present.
cOmplete, Mini Tablets, inhibit proteolytic activity in small extraction volumes (up to 10 ml). If you are working with a larger volume (up to 50 ml) we recommend to use a different cOmplete product. The composition of the cOmplete Tablet is identical to the cOmplete, Mini Tablet, therefore comparable results are achieved with both product types.
Features and Benefits
Use cOmplete, Mini Protease Inhibitor Tablets to protect your proteins from a wide range of proteases. In just minutes, uninhibited proteolytic activity can degrade the protein you have spent days isolating. Each of these convenient water-soluble tablets contains a blend of protease inhibitors that inhibits proteolytic activity from most cell types, including animals, plants, yeast, and bacteria. No weighing or measuring is necessary, ensuring consistent results.
- Easy-to-use: Simply drop a quick-dissolving tablet into your buffer.
- Complete protection: Instantly protect your proteins against a broad range of proteases.
- Flexible: Protect proteins in extracts from almost any tissue or cell, including animals, plants, yeast, bacteria, or fungi.
- Safe: Choose non-toxic inhibitors that pose no risk to you or those around you.
- Suitable for IMAC purification: Purify poly-histidine tagged proteins with cOmplete His-Tag Purification Resin.
Packaging
Ships on Wet Ice in some cases however, shipping conditions may vary in certain regions.
Components
Proprietary mixture of several protease inhibitors with broad inhibitory specificity.
Quality
Performance-tested with pancreas extract.
Physical form
Tablets in glass vials
Preparation Note
Working concentration: 1 tablet per 10 ml extraction solution
Working solution: Preparation of Working Solution
One cOmplete Mini Protease Inhibitor Tablet is sufficient for the inhibition of the proteolytic activity in 10 ml extraction solution. When very high proteolytic activity is present, one tablet should be used for 7 ml extraction buffer. Tablets can be added directly to the extraction medium. Alternatively, a stock solution (7 X conc.) can be prepared.
Stock solution (7 X conc.)
Dissolve one cOmplete Mini tablet in 1.5 ml dist. water or in 1.5 ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8 °C for 1 to 2 weeks, or at least 12 weeks at -15 to -25 °C.
Working solution: Preparation of Working Solution
One cOmplete Mini Protease Inhibitor Tablet is sufficient for the inhibition of the proteolytic activity in 10 ml extraction solution. When very high proteolytic activity is present, one tablet should be used for 7 ml extraction buffer. Tablets can be added directly to the extraction medium. Alternatively, a stock solution (7 X conc.) can be prepared.
Stock solution (7 X conc.)
Dissolve one cOmplete Mini tablet in 1.5 ml dist. water or in 1.5 ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8 °C for 1 to 2 weeks, or at least 12 weeks at -15 to -25 °C.
Reconstitution
Soluble in aqueous buffers, or add directly to extraction media. Alternatively, prepare 7x stock solutions in 1.5 ml water or 100 mM phosphate buffer, pH 7.0. Stock solution is stable for 1-2 weeks at 2 to 8 °C or at least 12 weeks at -15 to -25 °C; can be used in thiol-containing solutions at 15 to 25 °C.
Legal Information
cOmplete is a trademark of Roche
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
does not flash
Flash Point(C)
does not flash
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Paloma Araujo Cavalcante et al.
Infection and immunity, 88(7) (2020-04-29)
Staphylococcus aureus, an important cause of mastitis in mammals, is becoming increasingly problematic due to the development of resistance to conventional antibiotics. The ability of S. aureus to invade host cells is key to its propensity to evade immune defense
Ang Li et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 28(6), 1432-1441 (2020-04-30)
Adeno-associated viral (AAV) vectors are a leading candidate for the delivery of CRISPR-Cas9 for therapeutic genome editing in vivo. However, AAV-based delivery involves persistent expression of the Cas9 nuclease, a bacterial protein. Recent studies indicate a high prevalence of neutralizing antibodies
The N-terminal set-beta protein isoform induces neuronal death
Trakhtenberg EF, et al.
The Journal of biological chemistry, 290(21), 13417-13426 (2015)
Essential role for smooth muscle cell stromal interaction molecule-1 in myocardial infarction.
Mali V, et al.
Journal of Hypertension, 36(2), 377-386 (2018)
Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Dettling S, et al.
Clinical Cancer Research, 24(12), 2951-2962 (2018)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service